The most recent update to the ANDROGel label was on February 27, 2023 [1].
What medical information was updated on the ANDROGel label?
The February 27, 2023 label update included new information regarding the drug's effectiveness and safety. It specifies that ANDROGel is indicated for the replacement therapy in adult males with hypogonadism, confirmed by both clinical presentation and laboratory tests [1].
When was ANDROGel first approved?
ANDROGel was initially approved by the U.S. Food and Drug Administration (FDA) in 2000 [2].
What are the potential side effects of ANDROGel?
Common side effects of ANDROGel can include increased blood pressure, prostate disorders, headache, and skin reactions at the application site, such as redness or itching [1]. More serious risks include cardiovascular events and potential effects on male fertility [3].
Are there different forms or strengths of ANDROGel?
ANDROGel is available as a topical gel [1]. It is typically applied once daily to the shoulders and upper arms [1].
What is the patent status for ANDROGel?
Information regarding specific patents for ANDROGel and their expiration dates can be found on DrugPatentWatch.com. The patent landscape for testosterone replacement therapies is complex and can involve multiple patents covering different aspects of the drug, formulation, and manufacturing [4].
How does ANDROGel compare to other testosterone therapies?
ANDROGel is one of several testosterone replacement therapies available. Other options include injections, pellets, and other topical formulations, each with different administration methods, pharmacokinetic profiles, and potential side effect profiles. The choice of therapy depends on individual patient needs and physician recommendations [3].